Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Paclitaxel +/- Bevacizumab vs Oxaliplatin and Capecitabine +/- Bevacizumab in Mucinous Ovarian or Fallopian Tube Cancer
NCT01081262Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, oxaliplatin, capecitabine in Mucinous epithelial ovarian cancer (MOC), fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Started Oct 2010; status: active, not recruiting.
02
Drugs
bevacizumaboxaliplatincapecitabine
03
Conditions
Mucinous epithelial ovarian cancer (MOC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01081262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01081262.